XSHE
002688
Market cap598mUSD
Oct 09, Last price
5.30CNY
1D
1.73%
1Q
7.94%
Jan 2017
-47.52%
IPO
-4.16%
Name
Jinhe Biotechnology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Founded in 1990 and headquartered in Dalian, China, Jinhe Biotechnology Co. Ltd. focuses on the development and distribution of animal health pharmaceuticals both domestically and internationally. The company provides chlortetracycline in a feed-grade formulation, an antimicrobial compound vital for preventing and treating conditions like white dysentery, enteritis, pneumonia, typhoid, paratyphoid, and cholera in poultry and livestock. Additionally, its offerings include chlortetracycline hydrochloride, utilized to combat pullorum disease, typhoid, swine enteritis, and other bacterial ailments such as paratyphoid and cholera. Jinhe Biotechnology extends its market reach globally, exporting these veterinary solutions to regions including the United States, Southeast Asia, Latin America, and Europe.
Key people
Dongxiao Wang
Chairman of the Board · since 2007
Fuzhong Li
Vice Chairman of the Board · since 2007
Youshan Niu
Chief Financial Officer · since 2014
Changxian Xie
General Manager, Director · since 2007
Yingzhen Guan
Deputy General Manager · since 2017
Mingsheng Jian
Deputy General Manager · since 2023
Deputy General Manager
Zhijun Wang
Deputy General Manager, Director · since 2014
Zhisheng Wang
Deputy General Manager · since 2023
Xibao Yun
Deputy General Manager · since 2023
Manman Lu
Secretary of the Board, Director · since 2023
Yueqing Wang
Staff Elected Director · since 2025
Xiaochuan Guo
Independent Director · since 2025
Independent Director · since 2023
Xiaoyan Xie
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||